Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have been approved in combination with endocrine therapy (ET) to treat estrogen receptor-positive (ER+) metastatic breast cancer (BC). However, drug resistance represents the leading cause of breast cancer patients mortality. This study aimed to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Belli, Stefania, Esposito, Daniela, Allotta, Alessandra, Servetto, Alberto, Ciciola, Paola, Pesapane, Ada, Ascione, Claudia M., Napolitano, Fabiana, Di Mauro, Concetta, Vigliar, Elena, Iaccarino, Antonino, De Angelis, Carmine, Bianco, Roberto, Formisano, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232479/
https://www.ncbi.nlm.nih.gov/pubmed/37258566
http://dx.doi.org/10.1038/s41523-023-00556-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232479/
https://www.ncbi.nlm.nih.gov/pubmed/37258566
http://dx.doi.org/10.1038/s41523-023-00556-9

Ejemplares similares